RAPT Therapeutics (NASDAQ:RAPT – Free Report) had its target price decreased by UBS Group from $10.00 to $2.00 in a research note published on Monday morning, Benzinga reports. UBS Group currently has a neutral rating on the stock.
RAPT has been the subject of a number of other research reports. HC Wainwright reissued a neutral rating on shares of RAPT Therapeutics in a report on Tuesday, August 20th. Wolfe Research reiterated a peer perform rating on shares of RAPT Therapeutics in a research note on Tuesday, May 14th. Nine equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of Hold and an average target price of $20.43.
Read Our Latest Analysis on RAPT
RAPT Therapeutics Stock Performance
RAPT Therapeutics (NASDAQ:RAPT – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.03. As a group, sell-side analysts forecast that RAPT Therapeutics will post -2.73 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of RAPT Therapeutics by 65.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,602 shares of the company’s stock valued at $59,000 after purchasing an additional 2,621 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in RAPT Therapeutics in the first quarter valued at about $97,000. XTX Topco Ltd bought a new position in RAPT Therapeutics in the second quarter valued at about $108,000. Hennion & Walsh Asset Management Inc. grew its position in RAPT Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after acquiring an additional 3,824 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new position in shares of RAPT Therapeutics in the first quarter worth about $161,000. 99.09% of the stock is owned by institutional investors.
About RAPT Therapeutics
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Featured Articles
- Five stocks we like better than RAPT Therapeutics
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Leveraged ETFs to Multiply Returns
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Stock Market Sectors: What Are They and How Many Are There?
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.